Alfacyte

About ILC Therapeutics

ILC Therapeutics is a private, preclinical-stage biotech company developing a first-in-class drug platform based on engineered Hybrid Interferons. The company's core technology aims to overcome the limitations of natural interferons by creating novel molecules with enhanced potency, stability, and reduced side effects for targeted diseases. With a recent £2.5 million financing round and a lead program in RSV, ILC is positioning itself in the high-value antiviral and immunology space, though it faces significant development and competitive risks common to early-stage platform companies.

Therapeutic Areas

Other Respiratory Syncytial Virus (RSV) Infection Drugs